Novel T-Cell Immunotherapies Market By Type of T-cell Therapy-
Novel T-Cell Immunotherapies Market By Disease Indication-
Novel T-Cell Immunotherapies Market By Region-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Novel T-Cell Immunotherapies Market Snapshot
Chapter 4. Global Novel T-Cell Immunotherapies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By T-cell Therapy Type Estimates & Trend Analysis
5.1. By T-cell Therapy Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By T-cell Therapy Type:
5.2.1. Activated T-cells
5.2.2. Virus Driven T-cells
5.2.3. Tregs
5.2.4. γδ T-cells
5.2.5. T-cell vaccines
5.2.6. NK T-cells
Chapter 6. Market Segmentation 2: By Disease Indications Estimates & Trend Analysis
6.1. By Disease Indications & Market Share, 2020& 2030
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Disease Indications:
6.2.1. Lung cancer
6.2.2. Breast Cancer
6.2.3. Cytomegalovirus Infection
6.2.4. Glioblastoma
6.2.5. Hepatocellular Carcinoma
6.2.6. Acute Myeloid Leukemia
6.2.7. Ovarian Cancer
6.2.8. Type 1 Diabetes Mellitus
6.2.9. Sarcoma
6.2.10. HIV infections
6.2.11. Pancreatic Cancer
6.2.12. Other Disease Indications
Chapter 7. Novel T-Cell Immunotherapies Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts By T-cell Therapy Type, 2021-2034
7.1.2. North America Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
7.1.3. North America Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Novel T-Cell Immunotherapies Market revenue (US$ Million) By T-cell Therapy Type, 2021-2034
7.2.2. Europe Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
7.2.3. Europe Novel T-Cell Immunotherapies Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Novel T-Cell Immunotherapies Market revenue (US$ Million) By T-cell Therapy Type, 2021-2034
7.3.2. Asia Pacific Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
7.3.3. Asia Pacific Novel T-Cell Immunotherapies Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Novel T-Cell Immunotherapies Market revenue (US$ Million) By T-cell Therapy Type, (US$ Million)
7.4.2. Latin America Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
7.4.3. Latin America Novel T-Cell Immunotherapies Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Novel T-Cell Immunotherapies Market revenue (US$ Million) By T-cell Therapy Type, (US$ Million)
7.5.2. Middle East & Africa Novel T-Cell Immunotherapies Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
7.5.3. Middle East & Africa Novel T-Cell Immunotherapies Market revenue (US$ Million) by country, (US$ Million) 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Atara Biotherapeutics
8.2.2. AlloVir
8.2.3. Eureka Therapeutics
8.2.4. Eutilex
8.2.5. GammaDelta Therapeutics
8.2.6. NexImmune
8.2.7. OSE Immunotherapeutics
8.2.8. Tevogen Bio
8.2.9. WindMIL Therapeutics
8.2.10. Acepodia
8.2.11. Adaptate Therapeutics
8.2.12. Adicet
8.2.13. Cytomed Therapeutics
8.2.14. Gadeta
8.2.15. IN8bio
8.2.16. Kiromic Biopharma
8.2.17. Lava Therapeutics
8.2.18. Takeda Pharmaceuticals
8.2.19. TC Biopharm
8.2.20. ImCheck Therapeutics
8.2.21. Expression Therapeutics LLC
8.2.22. Triumvira Immunologics
8.2.23. PureTech Health
8.2.24. PhosphoGam
8.2.25. Caladrius Biosciences
8.2.26. Eli Lilly and Company
8.2.27. Miltenyi Biotec
8.2.28. Sangamo Therapeutics (TxCell)
8.2.29. Cellenkos Inc.
8.2.30. Pfizer Inc.
8.2.31. PolTREG S.A..
8.2.32. Parvus Therapeutics
8.2.33. ILTOO Pharma
8.2.34. Philogen S.p.A.
8.2.35. TRACT Therapeutics, Inc.
8.2.36. REGiMMUNE Co, Ltd.
8.2.37. Roche
8.2.38. Celgene
8.2.39. AHEAD THERAPEUTICS S.L.
8.2.40. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.